Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of

Elena Priante1, Elena Tavella2, Elisa Girardi3

  • 1Department of Woman's and Child's Health, Unit of Neonatal Intensive Care, University of Padua, Padua, Italy.

Insights

New Italian guidelines restricting palivizumab for premature infants significantly increased respiratory syncytial virus hospitalizations. This study highlights the need to re-evaluate palivizumab coverage for preventing RSVH in vulnerable infants.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Public Health Policy

Background:

  • Premature infants face the highest risk of respiratory syncytial virus (RSV) infections.
  • Palivizumab is the sole licensed prophylaxis for RSV hospitalization (RSVH) in infants born before 35 weeks gestational age (wGA).
  • In 2016, Italian drug agency (AIFA) restricted palivizumab reimbursement, excluding infants born after 29 wGA.

Purpose of the Study:

  • To compare the incidence of RSVH in premature infants before and after AIFA's 2016 policy change on palivizumab eligibility.
  • To assess the impact of restricted palivizumab access on RSVH rates in neonatal intensive care units (NICUs).

Main Methods:

  • A retrospective cohort study involving 536 infants born between 29 and 35 wGA across three NICUs in northern Italy.
  • Data collected via electronic medical records and parental interviews, comparing two consecutive RSV seasons (2015-2016 vs. 2016-2017).
  • Analysis focused on RSVH rates, palivizumab administration, and hospitalizations for other respiratory viruses.

Main Results:

  • RSVH incidence rose significantly from 1.9% in the pre-policy season to 5.1% in the post-policy season (OR=2.77, p=0.045).
  • Among infants not receiving palivizumab, RSVH rates increased from 1.8% to 5.9% (OR=3.42, p=0.045).
  • Hospital admissions for respiratory viruses other than RSV showed no significant difference between the two seasons.

Conclusions:

  • Restricting palivizumab reimbursement led to a significant increase in RSVH among eligible infants.
  • The policy change did not affect hospitalizations for other respiratory viruses, suggesting a specific impact on RSV.
  • Future palivizumab coverage decisions should prioritize cost-benefit analyses considering RSVH prevention in high-risk infants.
Abstract

Related Concept Videos

Hospitals-II00:59

Hospitals-II

Hospitals provide inpatient and outpatient services. Inpatient services provide care to patients that stay in the hospital for an extended period, ranging from days to months. Examples of inpatient services include intensive care units, hospital wards, or surgeries. Outpatient services provide care to patients who come to a hospital for a diagnostic or treatment but do not stay overnight —for example, diagnostic tests, surgical procedures, or health education.
Nurses that work in...
1.1K
The Born-Haber Cycle02:44

The Born-Haber Cycle

Lattice Energy 
25.2K
Hospitals-I01:28

Hospitals-I

Hospitals offer medical and surgical care to the sick and injured, along with accommodation while they recover. At the same time, they also provide outpatient, emergency, psychiatric, and rehabilitation services to meet various community needs. In addition to providing medical care, hospitals also act as hubs for medical research and training. Hospitals use clinical procedures and evidence-based practice standards to deliver patient care. To deliver safe and efficient care, a nurse must stay up...
1.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.4K
Restriction Enzymes01:11

Restriction Enzymes

Restriction enzymes are bacterial enzymes used to cut DNA in a sequence-specific manner. To cleave DNA, they bind to specific palindromic sequences called restriction sites. Such palindromic DNA sequences or inverted repeats are commonly found in regions of functional significance, such as the origin of replication, gene operator sites, and regions containing transcription termination signals.
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
35.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.2K